Global Search

Hide Filters

Showing 2796 results

Caring for the mental health and wellbeing of our people
Press release / May 21, 2026

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali® NATALEE oral presentation to report…
Expected currency impact
Novartis financial data
Press release / May 17, 2026

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12…
Frequently asked questions
Fixed-income securities
Patients and Caregivers
About Clinical Trials
Ad hoc release / Apr 28, 2026

Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt

Ad-hoc-Mitteilung gemäss Art. 53 KR Erstes QuartalDer Nettoumsatz ging um –5% (kWk1, –1% USD) zurück, da Wachstumstreiber durch Einbussen durch Generika in den USA mehr als…